Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

被引：0
|
作者：
Qi, Jialei [1 ]
Endres, Sascha [1 ]
Yosifov, Deyan Yordanov [2 ]
Tausch, Eugen [2 ]
Dheenadayalan, Rashmi Priyadharshini [1 ]
Gao, Xiang [3 ]
Scheffold, Annika [4 ]
Seyfried, Felix [5 ]
Meyer, Luder [6 ]
Schneider, Christof [2 ]
Mertens, Daniel [1 ]
Gierschik, Peter [1 ]
Wist, Martin [1 ]
Stilgenbauer, Stephan [2 ]
Jebaraj, Billy Michael Chelliah [4 ]
机构：
[1] Univ Ulm, Ulm, Germany
[2] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[3] Univ Ulm, Internal Med 3, Ulm, Germany
[4] Ulm Univ, Dept Internal Med 3, Ulm, Germany
[5] Univ Hosp Ulm, Dept Pediat & Adolescent, Ulm, Germany
[6] Ulm Univ, Med Ctr, Ulm, Germany
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159427
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3139 / 3141
页数：3
相关论文
共 50 条
  • [1] CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations
    de Man, Jos
    Muller, Michelle
    Uitdehaag, Joost C. M.
    van Cauter, Freek
    van Gemert, Sander
    Hoffmann, Milan
    van Mil, Yvonne G. T. H.
    Mulder, Winfried R.
    Prinsen, Martine B. W.
    Sterrenburg, Jan Gerard
    Vu, Diep
    de Wit, Joeri
    Ensing, Erik
    Buijsman, Rogier C.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [2] Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib
    Naeem, Aishath S.
    Utro, Filippo
    Wang, Qing
    Cha, Justin
    Vihinen, Mauno
    Martindale, Stephen P.
    Zhou, Yinglu
    Tyekucheva, Svitlana
    Kim, Annette S.
    Fernandes, Stacey M.
    Fardoun, Rayan
    Saksena, Gordon
    Rhrissorrakrai, Kahn
    Levovitz, Chaya
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel
    Davids, Matthew S.
    Zain, Rula
    Smith, Edvard C., I
    Leshchiner, Ignaty
    Parida, Laxmi
    Getz, Gad
    Brown, Jennifer R.
    [J]. BLOOD, 2022, 140 : 6981 - 6982
  • [3] Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
    Zain, Rula
    Vihinen, Mauno
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [4] Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors
    Naeem, Aishath
    Li, Liang
    Utro, Filippo
    Cha, Justin
    Tsuji, Junko
    Fernandes, Stacey M.
    Azevedo, Roberta Santos
    Morelli, Francesca
    Wang, Zunqiu
    Shupe, Samantha J.
    Rhrissorrakrai, Kahn
    Levovitz, Chaya
    Danysh, Brian P.
    Kluge, Alexandria
    Davids, Matthew S.
    Leshchiner, Ignaty
    Parida, Laxmi
    Getz, Gad
    Brown, Jennifer R.
    [J]. BLOOD, 2023, 142
  • [5] Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
    Montoya, Skye
    Bourcier, Jessie
    Thompson, Meghan C.
    Noviski, Mark
    Tan, May
    Wang, Eric
    Mi, Xiaoli
    Brathaban, Nivetha
    Risso, Carla Barrientos
    Tsai, Daniel
    Ye, Jordan
    Jahn, Jacob
    Pardo, Gabriel
    Cabuhat, Lee
    Notti, Ryan
    Pardo, Alejandro
    Affer, Maurizio
    Yung, Stephanie
    Luliano, James
    Powers, Janine
    Robbins, Daniel W.
    Nawaratne, Vindhya
    Totiger, Tulasigeri M.
    Pena-Velasquez, Camila
    Rhodes, Joanna M.
    Zelenetz, Andrew D.
    Roeker, Lindsey E.
    Lu, Hao
    Linley, Adam
    Mato, Anthony R.
    Abdel-Wahab, Omar
    Taylor, Justin
    [J]. BLOOD, 2022, 140 : 1811 - 1813
  • [6] Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors
    Kawahata, Wataru
    Asami, Tokiko
    Irie, Takayuki
    Sawa, Masaaki
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (02) : 145 - 151
  • [7] Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
    Qi, Jialei
    Endres, Sascha
    Yosifov, Deyan Yordanov
    Tausch, Eugen
    Dheenadayalan, Rashmi Priyadharshini
    Gao, Xiang
    Mueller, Annika
    Schneider, Christof
    Mertens, Daniel
    Gierschik, Peter
    Wist, Martin
    Jebaraj, Billy Michael Chelliah
    Stilgenbauer, Stephan
    [J]. BLOOD ADVANCES, 2023, 7 (19) : 5698 - 5702
  • [8] Covalent Inhibitors of BTK in the Treatment of CLL
    Woyach, Jennifer A.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S32
  • [9] ON-TARGET BTK MUTATIONS PROMOTE RESISTANCE TO NONCOVALENT BTK INHIBITORS
    不详
    [J]. CANCER DISCOVERY, 2022, 12 (05) : 1179 - 1179
  • [10] Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)
    Zhu, Huayuan
    Sha, Yeqin
    Miao, Yi
    Qin, Shuchao
    Wu, Wei
    Xia, Yi
    Qiu, Tonglu
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    [J]. BLOOD, 2022, 140 : 4117 - 4118
12345